Activity of Imipenem-Cilastatin-Relebactam Against Carbapenem-Resistant Enterobacteriaceae

Grants and Contracts Details

StatusFinished
Effective start/end date6/26/176/25/19

Funding

  • Merck and Company Inc: $49,493.00